A brief published Thursday in Health Affairs analyzes how competition in pharmaceuticals is actually driving rapid price hikes instead of leading to lower costs.
The authors, Harvard Medical School’s Jonathan Darrow and Aaron Kesselheim, in their paper looked to determine why inter-brand and brand-generic competition “may fail to produce lower prices for patients.”
Darrow and Kesselheim also takes a look at “policy interventions which could address these shortcomings.”
“Such proposals include increasing the efficiency of generic drug approval, allowing temporary importation of drugs during domestic shortages or price fluctuations, and discouraging the improper use of patent exclusivities,” they write.
To read the full brief on Health Affairs, click here.
